Garcia 2012.

Methods	Randomised parallel‐group placebo‐controlled study
Participants	Reported as 41 participants with severe non‐atopic asthma uncontrolled despite daily high‐dose inhaled corticosteroids (with or without maintenance oral corticosteroids) plus a long‐acting beta2‐agonist
Interventions	Randomly assigned to receive omalizumab or placebo in a 1:1 ratio 16‐Week study
Outcomes	Reported as the following: The primary endpoint was change in expression of high‐affinity IgE receptor FceRI on blood basophils and plasmacytoid dendritic cells (pDC2) after 16 weeks. Impact on lung function and clinical parameters was also assessed
Notes	Funded by Novartis Pharma SAS
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Details not provided (conference abstract)
Allocation concealment (selection bias)	Unclear risk	Details not provided (conference abstract)
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Details not provided (conference abstract)
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Details not provided (conference abstract)
Selective reporting (reporting bias)	Unclear risk	Not possible to assess from conference abstract